AbbVie (ABBV) Price & Analysis

Compare

22,653 Followers

ABBV Stock Chart & Stats

Day’s Range― - ―

52-Week Range$163.52 - $218.66

Previous CloseN/A

Volume1.02M

Average Volume (3M)6.16M

Market Cap

$337.14B

Enterprise Value$340.28B

Total Cash (Recent Filing)$5.18B

Total Debt (Recent Filing)$69.89B

Price to Earnings (P/E)81.4

Beta0.33

Next Earnings

Jul 25, 2025

EPS Estimate

3.22

Last Dividend Ex-Date

Apr 15, 2025

Dividend Yield3.44%

Share Statistics

EPS (TTM)2.46

Shares Outstanding1,766,403,100

10 Day Avg. Volume4,558,435

30 Day Avg. Volume6,162,605

Financial Highlights & Ratios

PEG Ratio9.22

Price to Book (P/B)16.59

Price to Sales (P/S)0.00

P/FCF Ratio11.80

Enterprise Value/Market Cap1.01

Enterprise Value/Revenue1.52

Enterprise Value/Gross Profit7.66

Enterprise Value/Ebitda4.11

Forecast

1Y Price Target

$212.80

Price Target Upside14.73% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering17

AbbVie News

See All News >

Bulls Say, Bears Say

Bulls Say

FDA ApprovalEmrelis (Teliso-V) granted accelerated approval by the FDA for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression.

Obesity Market PotentialThe company sees significant upside in obesity due to the market size and low penetration rates, with potential backbone therapy through amylin.

Pipeline DevelopmentABBV's underappreciated mid-stage pipeline is expected to be ready for prime-time in the near future.

Bears Say

Pipeline OpportunitiesThe late-stage pipeline comprises mostly label expansions that offer less opportunity than those already approved.

Pipeline RiskA comparatively lighter late-stage pipeline and in therapeutic areas that may not scale to the current I&I franchise add risk to AbbVie's relative safety positioning.

Policy RiskA higher perceived policy risk than peers from PBM reform/MFN discounting adds risk to AbbVie's relative safety positioning.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

0.07% Insiders

21.49% Mutual Funds

14.10% Other Institutional Investors

41.98% Public Companies and Individual Investors

Detailed Ownership Overview >

ABBV FAQ

What was AbbVie’s price range in the past 12 months?

AbbVie lowest stock price was $163.52 and its highest was $218.66 in the past 12 months.

What is AbbVie’s market cap?

AbbVie’s market cap is $337.14B.

When is AbbVie’s upcoming earnings report date?

AbbVie’s upcoming earnings report date is Jul 25, 2025 which is in 37 days.

How were AbbVie’s earnings last quarter?

AbbVie released its earnings results on Apr 25, 2025. The company reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.379 by $0.081.

Is AbbVie overvalued?

According to Wall Street analysts AbbVie’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does AbbVie pay dividends?

AbbVie pays a Quarterly dividend of $1.64 which represents an annual dividend yield of 3.44%. See more information on AbbVie dividends here

What is AbbVie’s EPS estimate?

AbbVie’s EPS estimate is 3.22.

How many shares outstanding does AbbVie have?

AbbVie has 1,766,403,100 shares outstanding.

What happened to AbbVie’s price movement after its last earnings report?

AbbVie reported an EPS of $2.46 in its last earnings report, beating expectations of $2.379. Following the earnings report the stock price went up 3.155%.

Which hedge fund is a major shareholder of AbbVie?

Currently, no hedge funds are holding shares in ABBV

AbbVie Stock Smart Score

Outperform

Fundamentals

Return on Equity

88.15%

Trailing 12-Months

Asset Growth

-8.54%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

AbbVie

AbbVie Inc. is a global biopharmaceutical company engaged in the discovery, development, manufacturing, and sale of a broad range of pharmaceutical products. The company focuses primarily on key therapeutic areas, including immunology, oncology, virology, and neuroscience. AbbVie is known for its flagship drug, Humira, which has been a leading treatment in immunology. The company's pipeline includes a range of new products and formulations intended to address complex and serious health conditions.

ABBV Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted strong performance in the Ex-Humira platform and increased guidance, driven by growth in immunology and neuroscience. However, there were significant challenges in Humira and aesthetics sales, with competitive pressures impacting Imbruvica. Overall, the company shows strong momentum despite these challenges.Read More>

ABBV Net revenue Breakdown

47.36% Immunology

15.97% Neuroscience

11.86% Other Key Products

11.64% Oncology

13.17% Other

ABBV Stock 12 Month Forecast

Average Price Target

$212.80

▲(14.73%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"154":"$154","251":"$251","178.25":"$178.3","202.5":"$202.5","226.75":"$226.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":250,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$250.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":212.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$212.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":170,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$170.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[154,178.25,202.5,226.75,251],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,186.99,191.83692307692309,196.68384615384616,201.53076923076924,206.3776923076923,211.2246153846154,216.07153846153847,220.91846153846154,225.76538461538462,230.6123076923077,235.45923076923077,240.30615384615385,245.15307692307692,{"y":250,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,186.99,188.97538461538463,190.96076923076924,192.94615384615386,194.93153846153848,196.9169230769231,198.90230769230772,200.8876923076923,202.87307692307692,204.85846153846154,206.84384615384616,208.82923076923078,210.8146153846154,{"y":212.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,186.99,185.68307692307692,184.37615384615384,183.06923076923078,181.7623076923077,180.45538461538462,179.14846153846153,177.84153846153848,176.5346153846154,175.2276923076923,173.92076923076922,172.61384615384617,171.30692307692308,{"y":170,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":155.59,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.4,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":184.74,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.17,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":191.8,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.8,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":178.42,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.43,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":207.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":193.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.99,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >